Lupron (leuprolide; Takeda/AbbVie) is a gonadotropin-releasing hormone (GnRH) agonist which acts on the pituitary gland in the brain to stimulate luteinizing hormone (LH) release, resulting in a temporary surge in serum testosterone levels known as “flare.” With continued use, GnRH agonists such as Lupron cause downregulation of GnRH receptors in the pituitary gland, generating a significant reduction in LH and follicle-stimulating hormone secretion. This has the effect of complete shutdown of testosterone production in the testes, resulting in chemical castration where levels of the hormone drop by up to 95% and tumor growth is significantly reduced.
TABLE OF CONTENTS
4 Product Profiles
4 Lupron : Prostate cancer
LIST OF FIGURES
6 Figure 1: Lupron sales for prostate cancer across the US, Japan, and five major EU markets, by country, 2017–26
LIST OF TABLES
7 Table 1: Lupron sales for prostate cancer across the US, Japan, and five major EU markets, by country ($m), 2017–26
Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is Suite 1, 3rd Floor, 11 - 12 St. James's Square, London, England, SW1Y 4LB. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.